EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Jiuwei Xiaozhi Decoction Alleviates High‐Fat Diet‐Induced MASLD by Suppressing Hepatic SREBP2 ‐Driven Cholesterogenesis and Restoring PPARα ‐Mediated Fatty Acid Oxidation

Youcheng Ma, Xinrui Gao, Ji Wang iD, Lingru Li, Zhen Huang iD, Fangli Li iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Youcheng Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, PPAR alpha, Sterol Regulatory Element Binding Protein 2, Cholesterol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical and Health Three Famous Project (Sanming Project) of Shenzhen, Natural Science Foundation of Shenzhen Municipality, Special Fund for Scientific and Technological Innovation of Shenzhen Longgang District.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Jiuwei Xiaozhi Decoction (JWXZ) is a nine‐herb traditional Chinese medicine formula clinically used for hepatic steatosis and dyslipidemia, but its chemical basis and pharmacological mechanisms in metabolic dysfunction‐associated steatotic liver disease (MASLD) remain incompletely defined. The chemical profile of JWXZ was characterized by UHPLC‐HRMS/MS. Its therapeutic effects were evaluated in a high‐fat diet (HFD)‐induced mouse model of MASLD, followed by hepatic transcriptomic analysis, network pharmacology, molecular docking, Western blotting, and immunofluorescence validation. UHPLC‐HRMS/MS identified 178 chemical constituents in JWXZ, including phenolic acids, flavonoids, flavonoid glycosides, alkaloids, isoflavones, and coumarins. In HFD‐fed mice, JWXZ attenuated body weight gain, white adipose accumulation, dyslipidemia, hepatic triglyceride and cholesterol accumulation, serum transaminase elevation, and hepatic steatosis, while improving glucose tolerance and partially restoring whole‐body metabolic flexibility. Hepatic transcriptomics identified 124 HFD‐dysregulated genes reversed by high‐dose JWXZ, with prominent enrichment in cholesterol and sterol biosynthesis, endoplasmic reticulum proteostasis, oxidative stress response, and PPARα‐related lipid handling. Integrated transcriptomic and network pharmacology analyses further identified 157 shared targets and 18 overlapping pathways, converging mainly on cholesterol metabolism and PPAR signaling. Protein‐level validation showed that JWXZ suppressed SREBP2 proteolytic activation, reduced nuclear SREBP2 abundance, and downregulated HMGCR, SQLE, and PCSK9, indicating inhibition of the hepatic cholesterogenic program. In parallel, JWXZ restored nuclear PPARα abundance and CPT1A expression, consistent with reactivation of fatty acid oxidation. JWXZ also reduced hepatic EGFR phosphorylation and lowered hepatic and circulating TNF‐α, IL‐6, IL‐1β, and MCP‐1 levels. Molecular docking provided supportive evidence for potential interactions between representative JWXZ constituents and key regulators, including naringin‐HMGCR, chlorogenic acid‐SQLE, rhoifolin‐PPARα, and rhoifolin‐SREBP2. These findings suggest that JWXZ ameliorates HFD‐induced MASLD mainly by rebalancing hepatic lipid metabolism through coordinated suppression of SREBP2‐mediated cholesterogenesis and restoration of PPARα‐mediated fatty acid oxidation, with associated attenuation of EGFR‐linked inflammatory responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalPPAR alphaSterol Regulatory Element Binding Protein 2CholesterolFatty AcidsNon-alcoholic Fatty Liver DiseaseFatty LiverAnimalsDiet, High-FatMaleLiverMiceMolecular Docking SimulationMice, Inbred C57BLOxidation-ReductionLipid MetabolismNetwork Pharmacology

Stichwörter der Autor:innen

Jiuwei Xiaozhi decoctionPPARαSREBP2hepatic lipid metabolismmetabolic dysfunction‐associated steatotic liver diseasenetwork pharmacologytraditional Chinese medicine

Substanzen

Drugs, Chinese HerbalPPAR alphaSterol Regulatory Element Binding Protein 2CholesterolFatty Acids

Autor:innen und Institutionen

  • Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, China.
  • National Institute of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China.

ORCID-Profile: Ji Wang, Zhen Huang, Fangli Li

Förderung

  • Medical and Health Three Famous Project (Sanming Project) of Shenzhen
  • Natural Science Foundation of Shenzhen Municipality
  • Special Fund for Scientific and Technological Innovation of Shenzhen Longgang District

Zitieren

APA

Ma, Y., Gao, X., Wang, J., Li, L., Huang, Z., & Li, F. (2026). Jiuwei Xiaozhi Decoction Alleviates High‐Fat Diet‐Induced MASLD by Suppressing Hepatic SREBP2 ‐Driven Cholesterogenesis and Restoring PPARα ‐Mediated Fatty Acid Oxidation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70371

Vancouver

Ma Y, Gao X, Wang J, Li L, Huang Z, Li F. Jiuwei Xiaozhi Decoction Alleviates High‐Fat Diet‐Induced MASLD by Suppressing Hepatic SREBP2 ‐Driven Cholesterogenesis and Restoring PPARα ‐Mediated Fatty Acid Oxidation. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70371

BibTeX
@article{Ma2026,
  author = {Ma, Youcheng and Gao, Xinrui and Wang, Ji and Li, Lingru and Huang, Zhen and Li, Fangli},
  title = {Jiuwei Xiaozhi Decoction Alleviates High‐Fat Diet‐Induced MASLD by Suppressing Hepatic SREBP2 ‐Driven Cholesterogenesis and Restoring PPARα ‐Mediated Fatty Acid Oxidation},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70371}
}
Kostenlos starten →